Hualan Biological Vaccine Inc. (SHE:301207)

China flag China · Delayed Price · Currency is CNY
19.64
+0.22 (1.13%)
Mar 10, 2026, 12:54 PM CST
12.23%
Market Cap 11.55B
Revenue (ttm) 976.44M
Net Income (ttm) 70.46M
Shares Out 595.00M
EPS (ttm) 0.12
PE Ratio 163.99
Forward PE 10.73
Dividend 0.60 (3.09%)
Ex-Dividend Date Oct 27, 2025
Volume 3,113,463
Average Volume 11,170,492
Open 18.97
Previous Close 19.42
Day's Range 18.97 - 19.77
52-Week Range 14.45 - 27.88
Beta 0.83
RSI 40.92
Earnings Date Mar 28, 2026

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetic engineering biological products in China. The company offers influenza vaccine (split virion), recombinant hepatitis B vaccine (hansenula polymorpha), meningococcal polysaccharide vaccine, influenza vaccine (split virion) quadrivalent, and meningococcal polysaccharide vaccine. It also sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 748
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301207
Full Company Profile

Financial Performance

In 2024, Hualan Biological Vaccine's revenue was 1.13 billion, a decrease of -53.21% compared to the previous year's 2.41 billion. Earnings were 205.52 million, a decrease of -76.10%.

Financial Statements

News

There is no news available yet.